僅用于工業(yè)應(yīng)用或科學(xué)研究，不可用于人類或動(dòng)物的臨床診斷或治療，非藥用. Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 （Ang-2） from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects